Chief Academic Officer, Heart, Vascular and Thoracic Institute, Cleveland

Cleveland Clinic, Dept. Cardiovascular Medcn

Printed as of 7/13/2025

## **Disclosures**

# Personal Commercial (17)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AbbVie, Inc.	Research/Research Grants ‡ TRAVERSE	Significant (>= \$5,000)	Other
Amgen	Research/Research Grants ‡ GLAGOV	Significant (>= \$5,000)	Prevention
Arrowhead	Research/Research Grants ‡ CAPITAN Trial	Significant (>= \$5,000)	Prevention
Astra Zeneca	Research/Research Grants ‡ STRENGTH	Significant (>= \$5,000)	Prevention Vascular Medicine
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ Tactic, Crest, Sport	Significant (>= \$5,000)	Prevention
Bristol Myers Squibb	Research/Research Grants ‡ Valor Trial	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bristol-Myers Squibb Company	Research/Research Grants ‡ Valor Trial	Significant (>= \$5,000)	Valvular Heart Disease
CRSPR Therapeutics	Research/Research Grants	None (\$0)	Prevention
Editor, Current Cardiology Reports (Springer Nature	Other - Journal Editor	Significant (>= \$5,000)	General Cardiology
Eli Lilly	Research/Research Grants ‡ ACCELERATE. SURMOUNT, ACCLAIM	Significant (>= \$5,000)	Vascular Medicine Prevention
Esperion Therapeutics	Research/Research Grants ‡ CLEAR trial	Significant (>= \$5,000)	Prevention
Kardigan	Research/Research Grants ‡ KARDINAL. KATALYST	Significant (>= \$5,000)	Prevention
Medtronic	Research/Research Grants	None (\$0)	Arrhythmias and Clinical EP
Mineralys	Research/Research Grants ‡ Protocol MLS-101-202 and Protocol MLS-101- 203	Significant (>= \$5,000)	General Cardiology
New Amsterdam Pharmaceuticals	Research/Research Grants ‡ TANDEM	Significant (>= \$5,000)	Prevention
Novartis	Research/Research Grants ‡ Lp(a)-Horizons	Significant (>= \$5,000)	Prevention
Silence Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Prevention
	‡ Apollo		

# Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Novartis	Other - Non-compensated speaker	None (\$0)	Prevention

## Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

# Institutional Financial Decision-Making Role (1)

Funding Source Institutional Compensation Level

Funding Source Institutional Compensation Level

none None (\$0)

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

#### **Agreement**

Certified Education Attestation | Signed on 7/3/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement in the properties of the

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/3/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/3/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/3/2025

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.